{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T02:17:15Z","timestamp":1778033835300,"version":"3.51.4"},"reference-count":40,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1171459"],"award-info":[{"award-number":["APP1171459"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Occup Environ Med"],"accepted":{"date-parts":[[2024,5,10]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The increase in gabapentinoid prescribing is paralleling the increase in serious harms. To describe the low back pain workers compensation population whose management included a gabapentinoid between 2010 and 2017, and determine secular trends in, and factors associated with gabapentinoid use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analysed claim-level and service-level data from the Victorian workers\u2019 compensation programme between 1 January 2010 and 31 December 2017 for workers with an accepted claim for a low back pain injury and who had programme-funded gabapentinoid dispensing. Secular trends were calculated as a proportion of gabapentinoid dispensings per year. Poisson, negative binomial and Cox hazards models were used to examine changes over time in incidence and time to first dispensing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 17\u2009689 low back pain claimants, one in seven (14.7%) were dispensed at least one gabapentinoid during the first 2 years (n=2608). The proportion of workers who were dispensed a gabapentinoid significantly increased over time (7.9% in 2010 to 18.7% in 2017), despite a reduction in the number of claimants dispensed pain-related medicines. Gabapentinoid dispensing was significantly associated with an opioid analgesic or anti-depressant dispensing claim, but not claimant-level characteristics. The time to first gabapentinoid dispensing significantly decreased over time from 311.9\u2009days (SD 200.7) in 2010 to 148.2\u2009days (SD 183.1) in 2017.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The proportion of claimants dispensed a gabapentinoid more than doubled in the period 2010\u20132017; and the time to first dispensing halved during this period.<\/jats:p><\/jats:sec>","DOI":"10.1136\/oemed-2023-109369","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T17:21:28Z","timestamp":1716484888000},"page":"245-251","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Secular trends in gabapentinoid dispensing by compensated workers with low back pain: a retrospective cohort study"],"prefix":"10.1136","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7335-8842","authenticated-orcid":false,"given":"Stephanie","family":"Mathieson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-9339","authenticated-orcid":false,"given":"Alex","family":"Collie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1628-7857","authenticated-orcid":false,"given":"Christopher G","family":"Maher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1258-5125","authenticated-orcid":false,"given":"Christina","family":"Abdel Shaheed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5033-6248","authenticated-orcid":false,"given":"Ting","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8534-195X","authenticated-orcid":false,"given":"Giovanni E","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-5949","authenticated-orcid":false,"given":"Michael F","family":"Di Donato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"2024080118102411000_81.5.245.1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00098-X"},{"key":"2024080118102411000_81.5.245.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jot.2021.07.005"},{"key":"2024080118102411000_81.5.245.3","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1097\/JOM.0000000000002628","article-title":"Filing a workers' compensation claim for low back pain and associated factors: analysis of 2015 national health interview survey","volume":"64","author":"Kyung","year":"2022","journal-title":"J Occup Environ Med"},{"key":"2024080118102411000_81.5.245.4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10926-020-09906-x","article-title":"Comparison of compensated low back pain claims experience in Australia with limb fracture and non-specific limb condition claims: a retrospective cohort study","volume":"31","author":"Di Donato","year":"2021","journal-title":"J Occup Rehabil"},{"key":"2024080118102411000_81.5.245.5","unstructured":"National Institute for Health and Care Excellence (NICE) . Low back pain and sciatica in over 16S: assessment and management. 2020. Available: https:\/\/www.nice.org.uk\/guidance\/ng59 [Accessed 19 Oct 2023]."},{"key":"2024080118102411000_81.5.245.6","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0000000000001311"},{"key":"2024080118102411000_81.5.245.7","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1097\/BRS.0b013e318145a731","article-title":"Relationship between early opioid prescribing for acute occupational low back pain and disability duration, medical costs, subsequent surgery and late opioid use","volume":"32","author":"Webster","year":"2007","journal-title":"Spine (Phila Pa 1976)"},{"key":"2024080118102411000_81.5.245.8","doi-asserted-by":"publisher","DOI":"10.1136\/oemed-2018-105626"},{"key":"2024080118102411000_81.5.245.9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajim.23306","article-title":"Workers' compensation prescription medication patterns and associated outcomes","volume":"65","author":"Freeman","year":"2022","journal-title":"American J Industrial Med"},{"key":"2024080118102411000_81.5.245.10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/15563650.2021.1965159","article-title":"Characteristics of fatal gabapentinoid-related poisoning in Australia, 2000-2020","volume":"60","author":"Darke","year":"2022","journal-title":"Clin Toxicol (Phila)"},{"key":"2024080118102411000_81.5.245.11","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.sapharm.2018.06.018","article-title":"Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: an analysis of the food and drug administration adverse events reporting system (FAERS)","volume":"15","author":"Evoy","year":"2019","journal-title":"Res Social Adm Pharm"},{"key":"2024080118102411000_81.5.245.12","unstructured":"Viatris . Austrlian product information - Lyrica (Pregabalin). 2022. Available: https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepositorynsf\/pdf?OpenAgent&id=CP-2010-PI-04219-3&d=20230922172310101 [Accessed 19 Oct 2023]."},{"key":"2024080118102411000_81.5.245.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1704633"},{"key":"2024080118102411000_81.5.245.14","doi-asserted-by":"crossref","unstructured":"Schaffer AL , Busingye D , Chidwick K , et al . Pregabalin prescribing patterns in Australian general practice, 2012 to 2018. BJGP Open 2021;5. doi:10.3399\/bjgpopen20X101120","DOI":"10.3399\/bjgpopen20X101120"},{"key":"2024080118102411000_81.5.245.15","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00586-017-5178-4","article-title":"Worsening trends in analgesics recommended for spinal pain in primary care","volume":"27","author":"Mathieson","year":"2018","journal-title":"Eur Spine J"},{"key":"2024080118102411000_81.5.245.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32586-7"},{"key":"2024080118102411000_81.5.245.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614292"},{"key":"2024080118102411000_81.5.245.18","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2022.100579","article-title":"Trends in gabapentinoid prescribing in UK primary care using the clinical practice research datalink: an observational study","volume":"27","author":"Ashworth","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2024080118102411000_81.5.245.19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/fcp.12726","article-title":"Gabapentinoid use in French most precarious populations: insight from Lyon permanent access to healthcare (PASS) units, 2016-1Q2021","volume":"36","author":"Chappuy","year":"2022","journal-title":"Fundam Clin Pharmacol"},{"key":"2024080118102411000_81.5.245.20","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1097\/JOM.0000000000002085","article-title":"Gabapentinoid and opioid utilization and cost trends among injured workers","volume":"63","author":"Liu","year":"2021","journal-title":"J Occup Environ Med"},{"key":"2024080118102411000_81.5.245.21","unstructured":"Australian Bureau of Statistics . Australian and New Zealand Standard Classification of Occupations. Version 12. Canberra: Australian Bureau of Statistics, 2013."},{"key":"2024080118102411000_81.5.245.22","unstructured":"Australian Bureau of Statistics . Socio-economic indexes for areas (SEIFA) 2011 ABS catalogue No.2033.0.55.001. Canberra Commonwealth of Australia; 2013."},{"key":"2024080118102411000_81.5.245.23","unstructured":"Department of Health and Aged Care . Measuring remoteness: accessibility\/remoteness index of Australia (ARIA) revised edition. Occasional papers: new series number 14. Canberra Department of Health and Aged Care; 2001."},{"key":"2024080118102411000_81.5.245.24","unstructured":"National Institute for Health and Care Excellence . Neuropathic pain in adults: pharmacological management in non-specialist settings. clinical guideline [CG173]. 2020. Available: https:\/\/wwwniceorguk\/guidance\/cg173 [Accessed 27 Feb 2024]."},{"key":"2024080118102411000_81.5.245.25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002369","article-title":"Benefits and safety of gabapentinoids in chronic low back pain: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Shanthanna","year":"2017","journal-title":"PLoS Med"},{"key":"2024080118102411000_81.5.245.26","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.171333"},{"key":"2024080118102411000_81.5.245.27","unstructured":"Department for Veterans Affairs\/ Department of Defense (VA\/DoD) . Clinical practice guideline for the diagnosis and treatment of low back pain. Version 3.0. 2022. Available: https:\/\/wwwhealthqualityvagov\/guidelines\/Pain\/lbp\/VADoDLBPCPGFinal508pdf [Accessed 27 Feb 2024]."},{"key":"2024080118102411000_81.5.245.28","unstructured":"The IQVIA Institute . Medicine use and spending in the U.S.: a review of 2017 and outlook to 2022. 2018. Available: https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/medicine-use-and-spending-in-the-us-review-of-2017-outlook-to-2022 [Accessed 27 Jun 2023]."},{"key":"2024080118102411000_81.5.245.29","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jat\/bkz036","article-title":"Misuse and mortality related to gabapentin and pregabalin are being under-estimated: a two-year post-mortem population study","volume":"43","author":"Nahar","year":"2019","journal-title":"J Anal Toxicol"},{"key":"2024080118102411000_81.5.245.30","doi-asserted-by":"publisher","DOI":"10.1111\/add.14412"},{"key":"2024080118102411000_81.5.245.31","doi-asserted-by":"crossref","first-page":"107926","DOI":"10.1016\/j.pharmthera.2021.107926","article-title":"The gabapentinoid drugs and their abuse potential","volume":"227","author":"Goins","year":"2021","journal-title":"Pharmacol Ther"},{"key":"2024080118102411000_81.5.245.32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40265-020-01432-7","article-title":"Abuse and misuse of pregabalin and gabapentin: a systematic review update","volume":"81","author":"Evoy","year":"2021","journal-title":"Drugs"},{"key":"2024080118102411000_81.5.245.33","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.676224","article-title":"Non-medical use of prescription gabapentinoids (Gabapentin and Pregabalin) in five European countries","volume":"12","author":"Fonseca","year":"2021","journal-title":"Front Psychiatry"},{"key":"2024080118102411000_81.5.245.34","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s40264-020-00985-6","article-title":"Current evidence on abuse and misuse of gabapentinoids","volume":"43","author":"H\u00e4gg","year":"2020","journal-title":"Drug Saf"},{"key":"2024080118102411000_81.5.245.35","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/bcp.13892","article-title":"Patterns of gabapentin and pregabalin use and misuse: results of a population-based cohort study in France","volume":"85","author":"Driot","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2024080118102411000_81.5.245.36","unstructured":"Pharmaceutical Benefits Advisory Committee . DUSC meeting, Pregabalin: 12 Month predicted versus actual analysis 2014. Available: https:\/\/www.pbs.gov.au\/pbs\/industry\/listing\/participants\/public-release-docs\/2014-10\/pregabalin-10-2014 [Accessed 27 Jun 2023]."},{"key":"2024080118102411000_81.5.245.37","unstructured":"Pharmaceutical Benefit Scheme . Drug utilisation sub-committee (DUSC) opioid analgesics pregabalin. 2020. Available: https:\/\/wwwpbsgovau\/info\/industry\/listing\/participants\/public-release-docs\/2020-02\/opioid-analgesics [Accessed 27 Jun 2023]."},{"key":"2024080118102411000_81.5.245.38","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/JOM.0000000000002636","article-title":"Drug prescription patterns as predictors of final workers compensation claim costs and closure: an updated analysis on an expanded cohort","volume":"64","author":"Tao","year":"2022","journal-title":"J Occup Environ Med"},{"key":"2024080118102411000_81.5.245.39","doi-asserted-by":"crossref","first-page":"e614","DOI":"10.1097\/j.pain.0000000000002433","article-title":"Trajectories of pregabalin use and their association with longitudinal changes in opioid and benzodiazepine use","volume":"163","author":"Schaffer","year":"2022","journal-title":"Pain"},{"key":"2024080118102411000_81.5.245.40","unstructured":"Penington Institute . Australia\u2019s annual overdose report. Melbourne Penington Institute; 2023."}],"container-title":["Occupational and Environmental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/oemed-2023-109369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T01:12:21Z","timestamp":1722561141000},"score":1,"resource":{"primary":{"URL":"https:\/\/oem.bmj.com\/lookup\/doi\/10.1136\/oemed-2023-109369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,6,3]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/oemed-2023-109369"],"URL":"https:\/\/doi.org\/10.1136\/oemed-2023-109369","relation":{},"ISSN":["1351-0711","1470-7926"],"issn-type":[{"value":"1351-0711","type":"print"},{"value":"1470-7926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}